BCL2L1 and B-cell chronic lymphocytic leukemia: Indeed, it has been shown that the type II anti-CD20 antibody, obinutuzumab, and to a lesser extent the standard of care rituximab, counteracted the microenvironment-dependent BCL-XL induction by inhibiting NF-kB in primary CLL and MCL cells [47,49].